The role of neoantigens in response to immune checkpoint blockade

International Immunology

Volumn 28, Issue 8, 2016, Pages 411-419

  Riaz, Nadeem ^a   Morris, Luc ^b,c   Havel, Jonathan J ^b   Makarov, Vladimir ^b   Desrichard, Alexis ^b   Chan, Timothy A ^a,b  

^a Department of Radiation Oncology ^*  (United States)

^b Human Oncology and Pathogenesis Program   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Immunotherapy; Mutation; Neoantigen

Indexed keywords

ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; NEOANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; AUTOANTIGEN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER GENETICS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MUTATION; NEOPLASM; PATIENT SELECTION; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; AUTOANTIGENS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MUTATION; NEOPLASMS; PATIENT SELECTION; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84988935389     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxw019     Document Type: Article

References (101)

1. Dunn, G. P., Old, L. J. and Schreiber, R. D. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137.
2. Dunn G. P., Bruce A. T., Ikeda H. et al. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991.
3. Lenschow, D. J., Walunas, T. L. and Bluestone, J. A. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
4. Smith-Garvin, J. E., Koretzky, G. A. and Jordan, M. S. 2009. T cell activation. Annu. Rev. Immunol. 27:591.
5. Morris, G. P. and Allen, P. M. 2012. How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nat. Immunol. 13:121.
6. Neefjes J., Jongsma M. L., Paul P. et al. 2011. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11:823.
7. Linsley P. S., Greene J. L., Brady W. et al. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793.
8. Brunet, J. F., Denizot, F., Luciani, M. F. et al. 1987. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267.
9. Linsley, P. S., Greene, J. L., Tan, P. et al. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176:1595.
10. Freeman, G. J., Lombard, D. B., Gimmi, C. D. et al. 1992. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J. Immunol. 149:3795.
11. Leach, D. R., Krummel, M. F. and Allison, J. P. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.
12. Hodi, F. S., O'Day, S. J., McDermott, D. F. et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711.
13. Schadendorf, D., Hodi, F. S., Robert, C. et al. 2015. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33:1889.
14. Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J. et al. 2015. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16:522.
15. Freeman, G. J., Long, A. J., Iwai, Y. et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027.
16. Dong, H., Strome, S. E., Salomao, D. R. et al. 2002. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793.
17. Zou, W. and Chen, L. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8:467.
18. Weber, J. S., D'Angelo, S. P., Minor, D. et al. 2015. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375.
19. Robert C., Long G. V., Brady B. et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:320.
20. Ribas, A., Puzanov, I., Dummer, R. et al. 2015. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16:908.
21. Herbst, R. S., Baas, P., Kim, D. W. et al. 2015. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540.
22. Borghaei, H., Paz-Ares, L., Horn, L. et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:1627.
23. Motzer, R. J., Escudier, B., McDermott, D. F. et al. 2015. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373:1803.
24. Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23.
25. Postow, M. A., Chesney, J., Pavlick, A. C. et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:2006.
26. Antonia, S., Goldberg, S. B., Balmanoukian, A. et al. 2016. Safety and antitumour activity of durvalumab plus tremelimumab in nonsmall cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17:299.
27. Hirano, F., Kaneko, K., Tamura, H. et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65:1089.
28. Brahmer, J. R., Tykodi, S. S., Chow, L. Q. et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455.
29. Herbst, R. S., Soria, J. C., Kowanetz, M. et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563.
30. Tumeh, P. C., Harview, C. L., Yearley, J. H. et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568.
31. Huard, B., Gaulard, P., Faure, F. et al. 1994. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 39:213.
32. Woo, S. R., Turnis, M. E., Goldberg, M. V. et al. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72:917.
33. Sakuishi, K., Apetoh, L., Sullivan, J. M. et al. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore antitumor immunity. J. Exp. Med. 207:2187.
34. Prehn, R. T. and Main, J. M. 1957. Immunity to methylcho, lanthrene-induced sarcomas. J. Natl Cancer Inst. 18:769.
35. Kripke, M. L. 1974. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl Cancer Inst. 53:1333.
36. Sensi, M. and Anichini, A. 2006. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin. Cancer Res. 12:5023.
37. Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P. et al. 2014. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14:135.
38. Simpson, A. J., Caballero, O. L., Jungbluth, A. et al. 2005. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5:615.
39. Kawakami, Y., Eliyahu, S., Sakaguchi, K. et al. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
40. Coulie, P. G., Brichard, V., Van Pel, A. et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
41. Wölfel, T., Van Pel, A., Brichard, V. et al. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759.
42. Schumacher, T. N. and Schreiber, R. D. 2015. Neoantigens in cancer immunotherapy. Science 348:69.
43. Mandelboim, O., Berke, G., Fridkin, M. et al. 1994. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67.
44. Mandelboim, O., Vadai, E., Fridkin, M. et al. 1995. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1:1179.
45. Coulie, P. G., Lehmann, F., Lethé, B. et al. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92:7976.
46. Wölfel, T., Hauer, M., Schneider, J. et al. 1995. A p16INK4ainsensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281.
47. Robbins, P. F., El-Gamil, M., Li, Y. F. et al. 1996. A mutated betacatenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.
48. Lennerz, V., Fatho, M., Gentilini, C. et al. 2005. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102:16013.
49. Zhou, J., Dudley, M. E., Rosenberg, S. A. et al. 2005. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. 28:53.
50. Matsushita, H., Vesely, M. D., Koboldt, D. C. et al. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400.
51. DuPage, M., Mazumdar, C., Schmidt, L. M. et al. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482:405.
52. Schreiber, R. D., Old, L. J. and Smyth, M. J. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565.
53. Liu, T., Yan, H., Kuismanen, S. et al. 2001. The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. Cancer Res. 61:7798.
54. Heemskerk, B., Kvistborg, P. and Schumacher, T. N. 2013. The cancer antigenome. EMBO J. 32:194.
55. Snyder, A., Makarov, V., Merghoub, T. et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371:2189.
56. Rizvi, N. A., Hellmann, M. D., Snyder, A. et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124.
57. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C. et al. 2013. Signatures of mutational processes in human cancer. Nature 500:415.
58. Lawrence, M. S., Stojanov, P., Polak, P. et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214.
59. Rooney, M. S., Shukla, S. A,. Wu, C. J. et al. 2015. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48.
60. Brown, S. D., Warren, R. L., Gibb, E. A. et al. 2014. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 24:743.
61. Cancer Genome Atlas Network. 2015. Genomic classification of cutaneous melanoma. Cell 161:1681.
62. Govindan, R., Ding, L., Griffith, M. et al. 2012. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121.
63. Cancer Genome Atlas Research Network. 2014. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:543.
64. Le, D. T., Uram, J. N., Wang, H. et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:2509.
65. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330.
66. Shinbrot, E., Henninger, E. E., Weinhold, N. et al. 2014. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 24:1740.
67. Kim, T. M., Laird, P. W. and Park, P. J. 2013. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 155:858.
68. Saeterdal, I., Bjørheim, J., Lislerud, K. et al. 2001. Frameshiftmutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Natl Acad. Sci. USA 98:13255.
69. Linnebacher, M., Gebert, J., Rudy, W. et al. 2001. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int. J. Cancer 93:6.
70. Gerlinger, M., Rowan, A. J., Horswell, S. et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883.
71. McGranahan, N. and Swanton, C. 2015. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15.
72. Morris, L. G., Riaz, N., Desrichard, A. et al. 2016 Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7:10051.
73. Andor, N., Graham, T. A., Jansen, M. et al. 2016. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22:105.
74. McGranahan, N., Furness, A. J., Rosenthal, R. et al. 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463.
75. Gubin, M. M., Zhang, X., Schuster, H. et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577.
76. Segal, N. H., Parsons, D. W., Peggs, K. S. et al. 2008. Epitope landscape in breast and colorectal cancer. Cancer Res. 68:889.
77. Snyder, A. and Chan, T. A. 2015. Immunogenic peptide discovery in cancer genomes. Curr. Opin. Genet. Dev. 30:7.
78. Alioto, T. S., Buchhalter, I., Derdak, S. et al. 2015. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat. Commun. 6:10001.
79. Xu, H., DiCarlo, J., Satya, R. V. et al. 2014. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics 15:244.
80. Van Allen, E. M., Miao, D., Schilling, B. et al. 2015. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207.
81. Nielsen, M., Lundegaard, C., Lund, O. et al. 2005. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57:33.
82. Larsen, M. V., Lundegaard, C., Lamberth, K. et al. 2007. Largescale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 8:424.
83. Nielsen, M., Lundegaard, C., Worning, P. et al. 2003. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12:1007.
84. Trolle, T., Metushi, I. G., Greenbaum, J. A. et al. 2015. Automated benchmarking of peptide-MHC class I binding predictions. Bioinformatics 31:2174.
85. Andreatta, M. and Nielsen, M. 2016. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32:511.
86. Nielsen, M., Lundegaard, C., Blicher, T. et al. 2007. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and-B locus protein of known sequence. PLoS One 2:e796.
87. Hugo, W., Zaretsky, J. M., Sun, L. et al. 2016. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:35.
88. Cohen, C. J., Gartner, J. J., Horovitz-Fried, M. et al. 2015. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125:3981.
89. Calis, J. J., Maybeno, M., Greenbaum, J. A. et al. 2013. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput. Biol. 9:e1003266.
90. Nielsen, M., Lund, O., Buus, S. et al. 2010. MHC class II epitope predictive algorithms. Immunology 130:319.
91. Andreatta, M., Karosiene, E., Rasmussen, M. et al. 2015. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification. Immunogenetics 67:641.
92. Kreiter, S., Vormehr, M., van de Roemer, N. et al. 2015. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:692.
93. Tran, E., Turcotte, S., Gros, A. et al. 2014. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641.
94. Linnemann, C., van Buuren, M. M., Bies, L. et al. 2015. Highthroughput epitope discovery reveals frequent recognition of neoantigens by CD4+ T cells in human melanoma. Nat. Med. 21:81.
95. van Rooij, N., van Buuren, M. M., Philips, D. et al. 2013. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31:e439.
96. Robbins, P. F., Lu, Y. C., El-Gamil, M. et al. 2013. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19:747.
97. Sivan, A., Corrales, L., Hubert, N. et al. 2015. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084.
98. Vétizou, M., Pitt, J. M., Daillère, R. et al. 2015. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079.
99. Vigneron, N., Stroobant, V., Van den Eynde, B. J. and van der Bruggen, P. 2013. Database of T cell-defined tumor antigens: the 2013 update. Cancer Immun. 13:15.
100. Erkes, D. A., Mohgbeli, T. and Snyder, C. M. 2015. Virus-specific CD8+ T cells infiltrate melanoma lesions and retain function despite high PD-1 expression. Society for Immunotherapy of Cancer Meeting (SITC 2015), November 4-8, 2015, National Harbor, MD, USA: Oral Abstract.
101. Birnbaum, M. E., Mendoza, J. L., Sethi, D. K. et al. 2014. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157:1073.